Status:
RECRUITING
DMD Voice: Qualitative Interviews With Patients and Caregivers
Lead Sponsor:
Red Nucleus Enterprise Solutions, LLC
Collaborating Sponsors:
Italfarmaco S.A
Conditions:
Duchenne Muscular Dystrophy (DMD)
Eligibility:
MALE
10+ years
Brief Summary
The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their ...
Eligibility Criteria
Inclusion
- Subsample A - Patients
- Eligible participants for Subsample A must:
- Have been treated with Givinostat for at least 2 years
- Be at least 10 years of age with signed consent of a parent or legal guardian
- Be currently taking givinostat
- Willing and able to participate in a video and/or audio recorded interview
- Subsample A - Caregivers
- Eligible caregivers for Subsample A must:
- Be a parent or legal guardian of an individual with DMD that has been taking givinostat for at least two years
- Willing and able to participate in a video and/or audio recorded interview
- Subsample B - Caregivers
- Eligible caregivers for Subsample B must:
- Provide care to an individual with DMD who is unable to raise their hands above their head as confirmed by the caregiver
- Reside in the United States or Canada
- Able to read, speak, and understand English
- Willing and able to participate in a video and/or audio recorded interview Have access to a stable internet connection
Exclusion
- \-
Key Trial Info
Start Date :
March 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT06925269
Start Date
March 31 2025
End Date
December 1 2026
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Red Nucleus
Yardley, Pennsylvania, United States, 19067